Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Raymond James Initiates Coverage On Ascendis Pharma with Strong Buy Rating, Announces Price Target of $271

Author: Benzinga Newsdesk | October 17, 2025 11:32am

Raymond James analyst Martin Auster initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Strong Buy rating and announces Price Target of $271.

Posted In: ASND